Literature DB >> 21873621

Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada.

Abhijat Kitchlu1, Kristin Clemens, Tara Gomes, Daniel G Hackam, David N Juurlink, Muhammad Mamdani, Michael Manno, Matthew J Oliver, Robert R Quinn, Rita S Suri, Ron Wald, Andrew T Yan, Amit X Garg.   

Abstract

BACKGROUND: Beta-blockers may be cardioprotective in patients receiving chronic dialysis. We examined cardiovascular outcomes among incident dialysis patients receiving beta-blocker therapy.
METHODS: We conducted a retrospective cohort study employing linked healthcare databases in Ontario, Canada. We studied all consecutive chronic dialysis patients aged≥66 years who initiated dialysis between 1 July 1991 and 31 July 2007. Patients were divided into three groups according to new medication use after the initiation of chronic dialysis. The three groups were patients initiated on beta-blockers, calcium channel blockers and statins only. Patients in the beta-blocker and calcium channel blocker groups could also be concurrently receiving a statin. The primary outcome was time to a composite endpoint of death, myocardial infarction, stroke or coronary revascularization.
RESULTS: There were a total of 1836 patients (504 beta-blocker, 570 calcium channel blocker and 762 statin-only users). Compared to statin-only use, beta-blocker use was not associated with improved cardiovascular outcomes [adjusted hazard ratio (aHR) 1.07, 95% confidence interval (CI) 0.92-1.23]. As expected, calcium channel blocker use was also not associated with improved cardiovascular outcomes (aHR 0.91, 95% CI 0.79-1.06). Among all subgroup analyses by beta-blocker attributes, only high-dose beta-blocker therapy was associated with better cardiovascular outcomes as compared to low-dose beta-blockers (aHR 0.50, 95% CI 0.29-0.88).
CONCLUSIONS: We observed no beneficial effect of beta-blocker use among patients receiving chronic dialysis relative to our comparator groups. Given current uncertainty around the cardioprotective benefits of beta-blockers in patients receiving dialysis, a large randomized clinical trial is warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21873621     DOI: 10.1093/ndt/gfr460

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  A Comparative Study of Carvedilol Versus Metoprolol Initiation and 1-Year Mortality Among Individuals Receiving Maintenance Hemodialysis.

Authors:  Magdalene M Assimon; M Alan Brookhart; Jason P Fine; Gerardo Heiss; J Bradley Layton; Jennifer E Flythe
Journal:  Am J Kidney Dis       Date:  2018-04-10       Impact factor: 8.860

2.  β-Blockers in dialysis patients: a nephrocardiology perspective.

Authors:  Gautam R Shroff; Charles A Herzog
Journal:  J Am Soc Nephrol       Date:  2014-10-30       Impact factor: 10.121

Review 3.  Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations.

Authors:  Srisakul Chirakarnjanakorn; Sankar D Navaneethan; Gary S Francis; W H Wilson Tang
Journal:  Int J Cardiol       Date:  2017-01-04       Impact factor: 4.164

Review 4.  Impact of drugs on intradialytic hypotension: Antihypertensives and vasoconstrictors.

Authors:  Tara I Chang
Journal:  Semin Dial       Date:  2017-07-05       Impact factor: 3.455

5.  The three-year incidence of major hemorrhage among older adults initiating chronic dialysis.

Authors:  Manish M Sood; Sarah E Bota; Eric McArthur; Moira K Kapral; Navdeep Tangri; Greg Knoll; Deborah Zimmerman; Amit X Garg
Journal:  Can J Kidney Health Dis       Date:  2014-09-02

6.  β-blockers in hemodialysis: simple questions, complicated answers.

Authors:  Gregory L Hundemer; Manish M Sood; Mark Canney
Journal:  Clin Kidney J       Date:  2020-12-22

7.  Comparative effectiveness of bisoprolol and carvedilol among patients receiving maintenance hemodialysis.

Authors:  Ping-Hsun Wu; Yi-Ting Lin; Jia-Sin Liu; Yi-Chun Tsai; Mei-Chuan Kuo; Yi-Wen Chiu; Shang-Jyh Hwang; Juan-Jesus Carrero
Journal:  Clin Kidney J       Date:  2021-01-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.